RECURRENT MALIGNANT SOLID NEOPLASM
Clinical trials for RECURRENT MALIGNANT SOLID NEOPLASM explained in plain language.
Never miss a new study
Get alerted when new RECURRENT MALIGNANT SOLID NEOPLASM trials appear
Sign up with your email to follow new studies for RECURRENT MALIGNANT SOLID NEOPLASM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Targeted drug ivosidenib tested in kids with rare, returning cancers
Disease control OngoingThis phase 2 trial tested the drug ivosidenib in children and young adults (ages 1 to 21) with solid tumors, lymphomas, or histiocytic disorders that have an IDH1 mutation and have either come back after treatment or not responded. The goal was to see if the drug could shrink or …
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 05:00 UTC
-
Vaccine trains immune system to hunt down cancer cells
Disease control TerminatedThis trial tests a vaccine called LabVax 3(22)-23, designed to help the immune system recognize and attack a protein called labyrinthin found on adenocarcinoma tumor cells. The study includes adults with advanced or metastatic adenocarcinoma and will evaluate the vaccine alone or…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: University of California, Davis • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New hope for kids with tough cancers: targeted drug shows promise in Gene-Matched tumors
Disease control OngoingThis study tests a drug called erdafitinib in children and young adults (ages 1 to 21) whose cancers have come back or are not responding to treatment and have specific changes in FGFR genes. The drug works by blocking enzymes that help cancer cells grow. The main goal is to see …
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for kids with rare cancers: targeted drug selpercatinib tested in phase 2 trial
Disease control OngoingThis phase 2 trial tests the drug selpercatinib in children and young adults (ages 1 to 21) with advanced cancers that have a specific genetic change called a RET alteration. The goal is to see if the drug can shrink tumors or stop them from growing. Only one participant has been…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a combination of copanlisib (a targeted drug) with nivolumab (an immunotherapy) in people with advanced solid tumors or lymphoma. Some participants will also receive a third drug, ipilimumab. The main goals are to find the safest dose and to monitor s…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Targeted drug shows promise for Hard-to-Treat brain and bile duct cancers
Disease control OngoingThis study tests a drug called olaparib in people with advanced cancers (like brain tumors, bile duct cancer, or other solid tumors) that have a specific gene change called IDH1 or IDH2 mutation. The drug works by blocking an enzyme that cancer cells need to grow. About 89 partic…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for kids with tough cancers: targeted drug attacks gene flaw
Disease control OngoingThis study tests a drug called ulixertinib in children and teens whose advanced cancers have a specific genetic change in the MAPK pathway. The goal is to see if the drug can shrink or control the tumor. About 20 participants with various solid tumors, lymphomas, or related disor…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for kids with rare cancers: targeted drug larotrectinib tested in small trial
Disease control OngoingThis phase 2 trial is testing the drug larotrectinib in children and young adults (ages 1 to 21) with advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that have a specific genetic change called an NTRK fusion. The cancers have either come back after treatment…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Targeted drug shows promise for kids with Tough-to-Treat cancers
Disease control OngoingThis study tested the drug ensartinib in 13 children and young adults (ages 1–21) whose cancers had come back or did not respond to treatment and had specific ALK or ROS1 gene changes. The goal was to see if the drug could shrink or stop tumor growth. While the drug targets cance…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Childhood cancer immunotherapy trial pulled before it started
Disease control TerminatedThis study was designed to test two immunotherapy drugs, nivolumab and ipilimumab, in children and young adults with cancers that returned or didn't respond to treatment and had many genetic mutations. The goal was to see if the drug combination was safe and could shrink tumors. …
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New hope for kids with rare cancers: drug targets tumor growth
Disease control OngoingThis phase 2 trial tests the drug cabozantinib in children and young adults with rare cancers like sarcomas, Wilms tumor, and others that have come back or not responded to treatment. Cabozantinib works by blocking enzymes that help tumors grow and form blood vessels. The study a…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New combo therapy tackles cancer in HIV patients
Disease control OngoingThis early-phase trial tests the safety of combining two cancer drugs, nivolumab and cabozantinib, in people with HIV who have advanced solid tumors. Only 8 participants were enrolled. The goal is to see if the combination is safe and can shrink or stabilize tumors.
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Experimental cocktail targets Hard-to-Treat cancers
Disease control TerminatedThis early-phase trial tests a new drug called ZEN003694, which blocks certain enzymes that help cancer grow, combined with two immunotherapy drugs (nivolumab and ipilimumab) that boost the immune system to attack cancer. The study includes 66 adults with advanced solid tumors, i…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New combo therapy targets rare childhood and adult cancers
Disease control OngoingThis study tests two immunotherapy drugs, tiragolumab and atezolizumab, in children and adults with rare cancers that have come back or not responded to treatment. These cancers lack certain genes (SMARCB1 or SMARCA4), making them hard to treat. The goal is to see if the drug com…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Keytruda takes on genetic weak spots in advanced tumors
Disease control OngoingThis phase 2 trial tests whether pembrolizumab (Keytruda) can shrink or control advanced solid tumors that have certain gene mutations (BRCA1, BRCA2, POLE, POLD1). The study enrolled 21 adults with cancers that have spread or come back. Researchers measure how many patients see t…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New drug cocktail targets Hard-to-Treat cancers in kids and young adults
Disease control OngoingThis early-phase trial tests a combination of three drugs (dasatinib, temsirolimus, and cyclophosphamide) in children and young adults with advanced solid tumors that have come back or not responded to standard treatment. The main goals are to find the safest dose and understand …
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New hope for kids with tough cancers: elimusertib trial launches
Disease control OngoingThis study tests a drug called elimusertib in children and young adults (ages 1 to 30) whose solid tumors have returned or not responded to treatment. The drug works by blocking an enzyme that cancer cells need to grow. The trial aims to find the safest dose and see if the drug c…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New combo targets debilitating fatigue in advanced cancer patients
Symptom relief OngoingThis study tests whether a drug called anamorelin, combined with physical activity and nutritional counseling, can reduce severe fatigue in people with advanced solid tumors that have spread or returned. About 129 participants with incurable cancers and high fatigue levels will r…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Can a sugar pill you know is fake fight cancer fatigue?
Symptom relief OngoingThis study tests whether an open labeled placebo—a pill with no active medicine that patients know is a placebo—can reduce fatigue in people with advanced cancer. About 100 participants will either receive the placebo or be placed on a waitlist. The goal is to see if simply takin…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2, PHASE3 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 09:06 UTC
-
Which method helps cancer patients best? new study tests palliative care delivery
Symptom relief OngoingThis study looks at two different methods—a Virtual Learning Collaborative or Technical Assistance—for delivering a palliative care program called ENABLE to people with advanced cancer and their caregivers. Palliative care focuses on relieving symptoms, reducing stress, and impro…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: NA • Sponsor: University of Rochester NCORP Research Base • Aim: Symptom relief
Last updated Jun 27, 2026 08:11 UTC
-
Can a steroid and exercise beat cancer fatigue?
Symptom relief OngoingThis study tests whether adding the steroid dexamethasone to a physical activity program helps reduce severe fatigue in people with advanced cancer. About 99 participants will take the drug or a placebo while doing strength and walking exercises. The goal is to see if the combina…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 08:06 UTC
-
Cancer treatment gets personal: MATCH trial tests Gene-Guided drugs
Knowledge-focused OngoingThis phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 02, 2026 05:00 UTC
-
Can DNA tests pick the right cancer drug for kids?
Knowledge-focused OngoingThis study screens children and teens with advanced solid tumors, lymphomas, or histiocytic disorders to find genetic changes in their cancer cells. Participants undergo biopsies and scans to identify mutations that can be targeted by specific drugs. The goal is to see if matchin…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Money help for cancer patients: study tests financial navigation
Knowledge-focused OngoingThis study looks at whether a financial navigation program can help cancer patients and their partners manage the high costs of treatment. About 331 people with advanced cancer will get either the program or usual care. The goal is to see if this support reduces financial hardshi…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: NA • Sponsor: SWOG Cancer Research Network • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Brain waves reveal: do unresponsive patients hear us in their final days?
Knowledge-focused TerminatedThis study uses a brain wave test (EEG) to check if cancer patients who seem unresponsive in their last days can still hear or feel. Researchers will measure brain activity when sounds or words are played. The goal is to help families and doctors understand what patients may expe…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
New study reveals hidden toll of Cancer-Related weight loss on families
Knowledge-focused OngoingThis study looks at how often cancer patients experience cachexia (unintentional weight loss and appetite loss) and how this affects both patients and their primary caregivers emotionally. About 192 patients and their caregivers will fill out questionnaires during supportive care…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
Expert panel boosts precision cancer care in new study
Knowledge-focused OngoingThis study looks at whether a special team of doctors and scientists (a genomic tumor board) can help more patients with advanced solid tumors get treatments that match their cancer's genetic makeup. About 1,284 patients will take part. The goal is to see if this team approach le…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: NA • Sponsor: SWOG Cancer Research Network • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC